BidaskClub upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a strong-buy rating in a report published on Thursday morning.
A number of other brokerages have also commented on OSUR. Canaccord Genuity reissued a buy rating and set a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. Zacks Investment Research raised OraSure Technologies from a hold rating to a buy rating and set a $23.00 price objective on the stock in a research note on Friday, February 9th. Finally, ValuEngine raised OraSure Technologies from a hold rating to a buy rating in a research note on Friday, March 2nd. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $22.25.
Shares of OraSure Technologies (NASDAQ:OSUR) opened at $18.06 on Thursday. OraSure Technologies has a 12 month low of $10.75 and a 12 month high of $23.01. The company has a market capitalization of $1,101.06, a PE ratio of 35.41, a PEG ratio of 5.04 and a beta of 1.60.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The firm had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. During the same period last year, the firm posted $0.13 earnings per share. The business’s revenue for the quarter was up 46.5% on a year-over-year basis. equities research analysts anticipate that OraSure Technologies will post 0.27 EPS for the current fiscal year.
In related news, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares in the company, valued at $504,507.75. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Elkfork Partners LLC acquired a new position in shares of OraSure Technologies in the fourth quarter worth approximately $143,000. Oppenheimer Asset Management Inc. acquired a new position in shares of OraSure Technologies in the third quarter worth approximately $186,000. Shikiar Asset Management Inc. acquired a new position in shares of OraSure Technologies in the fourth quarter worth approximately $207,000. Belpointe Asset Management LLC acquired a new position in shares of OraSure Technologies in the third quarter worth approximately $315,000. Finally, Sei Investments Co. lifted its stake in shares of OraSure Technologies by 422.4% in the third quarter. Sei Investments Co. now owns 14,925 shares of the medical instruments supplier’s stock worth $336,000 after acquiring an additional 12,068 shares during the period. 93.67% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “OraSure Technologies (OSUR) Stock Rating Upgraded by BidaskClub” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/18/orasure-technologies-osur-stock-rating-upgraded-by-bidaskclub.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.